-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
OPKO Health (NASDAQ:OPK) Reaches New 52-Week Low at $1.83
OPKO Health (NASDAQ:OPK) Reaches New 52-Week Low at $1.83
OPKO Health, Inc. (NASDAQ:OPK – Get Rating) hit a new 52-week low during trading on Monday . The stock traded as low as $1.83 and last traded at $1.83, with a volume of 24088 shares changing hands. The stock had previously closed at $1.88.
Analyst Upgrades and Downgrades
Separately, Piper Sandler lowered their price target on OPKO Health from $5.00 to $4.00 and set an "overweight" rating for the company in a research note on Friday, August 5th.
Get OPKO Health alerts:OPKO Health Trading Down 4.3 %
The company has a fifty day moving average of $2.33 and a two-hundred day moving average of $2.76. The company has a current ratio of 2.30, a quick ratio of 1.91 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -6.48 and a beta of 1.75.
OPKO Health (NASDAQ:OPK – Get Rating) last posted its earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). OPKO Health had a negative return on equity of 7.72% and a negative net margin of 14.18%. The company had revenue of $309.90 million during the quarter, compared to analyst estimates of $326.87 million. During the same quarter last year, the firm posted ($0.03) earnings per share. The firm's revenue for the quarter was down 30.0% compared to the same quarter last year. On average, research analysts expect that OPKO Health, Inc. will post -0.38 EPS for the current year.Insider Buying and Selling
In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 50,000 shares of the business's stock in a transaction dated Friday, September 23rd. The stock was bought at an average cost of $1.85 per share, for a total transaction of $92,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 197,706,694 shares in the company, valued at $365,757,383.90. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders purchased 900,000 shares of company stock worth $2,008,000. 40.97% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of OPK. Cornerstone Advisory LLC bought a new stake in shares of OPKO Health during the fourth quarter valued at approximately $29,000. Aigen Investment Management LP bought a new stake in shares of OPKO Health during the second quarter valued at approximately $29,000. Verition Fund Management LLC bought a new stake in shares of OPKO Health during the second quarter valued at approximately $36,000. Humankind Investments LLC bought a new stake in shares of OPKO Health during the first quarter valued at approximately $37,000. Finally, Laurion Capital Management LP bought a new stake in OPKO Health in the second quarter valued at $38,000. 27.83% of the stock is currently owned by institutional investors and hedge funds.
OPKO Health Company Profile
(Get Rating)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
See Also
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- Three Consumer Stocks That Could Outperform In Q4
- Comcast is an Asset Bonanza Priced Cheap
- Will Synthetic Biology Firm Amyris Post Net Income In 2024?
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
OPKO Health, Inc. (NASDAQ:OPK – Get Rating) hit a new 52-week low during trading on Monday . The stock traded as low as $1.83 and last traded at $1.83, with a volume of 24088 shares changing hands. The stock had previously closed at $1.88.
納斯達克股票代碼：OPK-GET Rating)週一的交易中創下52周新低。該股最低交易價格為1.83美元，最新報1.83美元，成交量為24088股。該股此前收盤價為1.88美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Separately, Piper Sandler lowered their price target on OPKO Health from $5.00 to $4.00 and set an "overweight" rating for the company in a research note on Friday, August 5th.
另外，派珀·桑德勒將OPKO Health的目標價從5.00美元下調至4.00美元，並在8月5日(星期五)的一份研究報告中為該公司設定了“增持”評級。
OPKO Health Trading Down 4.3 %
Opko Health股價下跌4.3%
The company has a fifty day moving average of $2.33 and a two-hundred day moving average of $2.76. The company has a current ratio of 2.30, a quick ratio of 1.91 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of -6.48 and a beta of 1.75.
該公司的50日移動均線切入位在2.33美元，200日移動均線切入位在2.76美元。該公司的流動比率為2.30，速動比率為1.91，債務權益比率為0.12。該股市值13.9億美元，市盈率為-6.48，貝塔係數為1.75。
Insider Buying and Selling
內幕買賣
In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 50,000 shares of the business's stock in a transaction dated Friday, September 23rd. The stock was bought at an average cost of $1.85 per share, for a total transaction of $92,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 197,706,694 shares in the company, valued at $365,757,383.90. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders purchased 900,000 shares of company stock worth $2,008,000. 40.97% of the stock is currently owned by insiders.
在OPKO Health的其他新聞中，首席執行官Phillip Md et Al Frost在一筆日期為9月23日星期五的交易中購買了50,000股OPKO股票。這隻股票的平均價格為每股1.85美元，總成交額為92,500.00美元。收購完成後，首席執行官現在直接擁有該公司197,706,694股，價值365,757,383.90美元。此次收購是在提交給美國證券交易委員會的一份文件中披露的，該文件可以通過美國證券交易委員會網站。在過去的90天裏，內部人士購買了90萬股公司股票，價值2,008,000美元。40.97%的股份目前由內部人士持有。
Institutional Inflows and Outflows
機構資金流入和流出
A number of large investors have recently modified their holdings of OPK. Cornerstone Advisory LLC bought a new stake in shares of OPKO Health during the fourth quarter valued at approximately $29,000. Aigen Investment Management LP bought a new stake in shares of OPKO Health during the second quarter valued at approximately $29,000. Verition Fund Management LLC bought a new stake in shares of OPKO Health during the second quarter valued at approximately $36,000. Humankind Investments LLC bought a new stake in shares of OPKO Health during the first quarter valued at approximately $37,000. Finally, Laurion Capital Management LP bought a new stake in OPKO Health in the second quarter valued at $38,000. 27.83% of the stock is currently owned by institutional investors and hedge funds.
一些大型投資者最近調整了對OPK的持有量。基石諮詢有限責任公司在第四季度購買了OPKO Health公司的新股份，價值約2.9萬美元。Aigen Investment Management LP在第二季度購買了OPKO Health的新股份，價值約29,000美元。Verition Fund Management LLC在第二季度購買了OPKO Health的新股份，價值約3.6萬美元。人類投資有限責任公司在第一季度購買了OPKO Health的新股份，價值約3.7萬美元。最後，Laurion Capital Management LP在第二季度購買了OPKO Health的新股份，價值3.8萬美元。該公司27.83%的股票目前由機構投資者和對衝基金持有。
OPKO Health Company Profile
Opko Health公司簡介
(Get Rating)
(獲取評級)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.
Opko Health，Inc.是一家醫療保健公司，在美國、愛爾蘭、智利、西班牙、以色列、墨西哥和國際上從事診斷和製藥業務。該公司的診斷部門經營着BioReference實驗室，該實驗室為疾病的檢測、診斷、評估、監測和治療提供實驗室測試服務，包括深奧測試、分子診斷、解剖病理學、遺傳學、婦女健康以及為醫生辦公室、診所、醫院、僱主和政府單位提供的矯正保健；以及在護理地點提供血液測試結果的新型診斷儀器系統，以及4KScore前列腺癌測試服務。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on OPKO Health (OPK)
- Three Consumer Stocks That Could Outperform In Q4
- Comcast is an Asset Bonanza Priced Cheap
- Will Synthetic Biology Firm Amyris Post Net Income In 2024?
- Can Caterpillar Claw Higher in a Falling Market?
- Is Dave & Buster's Immune to High Inflation and Lower Spending?
- 免費獲取StockNews.com關於OPKO健康的研究報告(OPK)
- 三隻可能在第四季度表現優異的消費類股
- 康卡斯特是廉價的資產財源
- 合成生物學公司Amyris將在2024年實現淨收益嗎？
- 卡特彼勒能否在下跌的市場中走得更高？
- Dave&Buster‘s能免受高通脹和低支出的影響嗎？
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
接受OPKO健康日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對OPKO Health和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧